Pfizer Inc. which can be found using ticker (PFE) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $45.00 and $27.00 calculating the mean target share price we have $31.46. (at the time of writing). Now with the previous closing price of $27.65 this indicates there is a potential upside of 13.8%. Also worth taking note is the 50 day moving average now sits at $27.50 and the 200 day MA is $29.18. The market cap for the company is 155.89B. The stock price for the company is currently $27.51 USD
The potential market cap would be $177,368,287,951 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $9.72 and a 0.93% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
